Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Oct 13

PMID 34641586

Citations 26

Authors

Jakob Lindberg

Johan Nilvebrant

Per-Ake Nygren

Fredrik Lehmann

Affiliations

Soon will be listed here.

Abstract

We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug conjugates used clinically as cancer treatments. While providing both efficacy and favorable tolerability, ADCs have limitations due to their size and complexity. Peptides as tumor-targeting carriers in peptide-drug conjugates (PDCs) offer a number of benefits. Melphalan flufenamide (melflufen) is a highly lipophilic PDC that takes a novel approach by utilizing increased aminopeptidase activity to selectively increase the release and concentration of cytotoxic alkylating agents inside tumor cells. The only other PDC approved currently for clinical use is Lu-dotatate, a targeted form of radiotherapy combining a somatostatin analog with a radionuclide. It is approved as a treatment for gastroenteropancreatic neuroendocrine tumors. Results with other PDCs combining synthetic analogs of natural peptide ligands with cytotoxic agents have been mixed. The field of drug conjugates as drug delivery systems for the treatment of cancer continues to advance with the application of new technologies. Melflufen provides a paradigm for rational PDC design, with a targeted mechanism of action and the potential for deepening responses to treatment, maintaining remissions, and eradicating therapy-resistant stem cells.

Citing Articles

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.

Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer.

Kotsifaki A, Maroulaki S, Karalexis E, Stathaki M, Armakolas A Int J Mol Sci. 2024; 25(17).

PMID: 39273251 PMC: 11394947. DOI: 10.3390/ijms25179302.

Strategies for Targeting Peptide-Modified Exosomes and Their Applications in the Lungs.

Qiu M, Zou J, Yang Z, Yang D, Wang R, Guo H Int J Nanomedicine. 2024; 19:8175-8188.

PMID: 39157733 PMC: 11328869. DOI: 10.2147/IJN.S472038.

Peptides for microbe-induced cancers: latest therapeutic strategies and their advanced technologies.

Lin Z, Assaraf Y, Kwok H Cancer Metastasis Rev. 2024; 43(4):1315-1336.

PMID: 39008152 DOI: 10.1007/s10555-024-10197-4.

DCTPep, the data of cancer therapy peptides.

Sun X, Liu Y, Ma T, Zhu N, Lao X, Zheng H Sci Data. 2024; 11(1):541.

PMID: 38796630 PMC: 11128002. DOI: 10.1038/s41597-024-03388-9.

References

Das S, Al-Toubah T, El-Haddad G, Strosberg J . Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019; 13(11):1023-1031. PMC: 7227421. DOI: 10.1080/17474124.2019.1685381. View

Lee J, Vinh N, Drinkwater N, Yang W, Sivaraman K, Schembri L . Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions. J Med Chem. 2019; 62(15):7185-7209. DOI: 10.1021/acs.jmedchem.9b00757. View

He R, Finan B, Mayer J, DiMarchi R . Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules. 2019; 24(10). PMC: 6572008. DOI: 10.3390/molecules24101855. View

Cooper B, Iegre J, Donovan D, Olwegard Halvarsson M, Spring D . Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem Soc Rev. 2020; 50(3):1480-1494. DOI: 10.1039/d0cs00556h. View

Richardson P, Oriol A, Larocca A, Blade J, Cavo M, Rodriguez-Otero P . Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2020; 39(7):757-767. PMC: 8078327. DOI: 10.1200/JCO.20.02259. View

Ahrens V, Bellmann-Sickert K, Beck-Sickinger A . Peptides and peptide conjugates: therapeutics on the upward path. Future Med Chem. 2012; 4(12):1567-86. DOI: 10.4155/fmc.12.76. View

Wickstrom M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjoberg P . Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017; 8(39):66641-66655. PMC: 5630444. DOI: 10.18632/oncotarget.18420. View

Beck A, Goetsch L, Dumontet C, Corvaia N . Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017; 16(5):315-337. DOI: 10.1038/nrd.2016.268. View

Yoo J, Park C, Yi G, Lee D, Koo H . Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. Cancers (Basel). 2019; 11(5). PMC: 6562917. DOI: 10.3390/cancers11050640. View

10.

Krop I, Kim S, Gonzalez-Martin A, LoRusso P, Ferrero J, Smitt M . Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(7):689-99. DOI: 10.1016/S1470-2045(14)70178-0. View

11.

Wang Z, Chen J, Little N, Lu J . Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery. Acta Biomater. 2020; 111:20-28. PMC: 7245299. DOI: 10.1016/j.actbio.2020.05.026. View

12.

Miettinen J, Kumari R, Traustadottir G, Huppunen M, Sergeev P, Majumder M . Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers (Basel). 2021; 13(7). PMC: 8036322. DOI: 10.3390/cancers13071527. View

13.

Altai M, Liu H, Ding H, Mitran B, Edqvist P, Tolmachev V . Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. J Control Release. 2018; 288:84-95. DOI: 10.1016/j.jconrel.2018.08.040. View

14.

Sgouros G, Bodei L, McDevitt M, Nedrow J . Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020; 19(9):589-608. PMC: 7390460. DOI: 10.1038/s41573-020-0073-9. View

15.

Ray A, Ravillah D, Das D, Song Y, Nordstrom E, Gullbo J . A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016; 174(3):397-409. PMC: 4961600. DOI: 10.1111/bjh.14065. View

16.

Singh R, Kumar S, Prasad D, Bhardwaj T . Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives. Eur J Med Chem. 2018; 151:401-433. DOI: 10.1016/j.ejmech.2018.04.001. View

17.

Hitzerd S, Verbrugge S, Ossenkoppele G, Jansen G, Peters G . Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids. 2014; 46(4):793-808. DOI: 10.1007/s00726-013-1648-0. View

18.

Frejd F, Kim K . Affibody molecules as engineered protein drugs. Exp Mol Med. 2017; 49(3):e306. PMC: 5382565. DOI: 10.1038/emm.2017.35. View

19.

Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N . In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013; 19(11):3019-31. PMC: 4098702. DOI: 10.1158/1078-0432.CCR-12-3752. View

20.

Hunter F, Barker H, Lipert B, Rothe F, Gebhart G, Piccart-Gebhart M . Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2019; 122(5):603-612. PMC: 7054312. DOI: 10.1038/s41416-019-0635-y. View